- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Exploring Results from CAPItello-291 Trial
William J. Gradishar, MD, examines the impact of the CAPItello-291 phase III trial on NCCN breast cancer guidelines, comparing the investigated drug to other PI3K pathway inhibitors and discussing its potential to shape future treatment strategies.
EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer
EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024
EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment
EP: 4.Tailoring CDK4/6 Inhibitor Treatment to Patient Needs
EP: 5.NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib
EP: 6.Exploring Results from CAPItello-291 Trial
EP: 7.Exploring Biomarker Testing and Personalized Treatments in Breast Cancer
EP: 8.NCCN Guidelines Revisions and ASCO 2024 Research Outlook
EP: 9.Emerging Breast Cancer Therapies and Closing Thoughts
- In November 2023, capivasertib received FDA approval for use in advanced hormone receptor-positive breast cancer based on the results from the CAPItello-291 phase III trial. How has capivasertib been integrated into the NCCN guidelines for breast cancer?
- What are your thoughts on sequencing of capivasertib use in the management of HR+ breast cancer?
- How does capivasertib compare to other PI3K pathway inhibitors alpelisib and inavolisib from safety and efficacy standpoints?
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link
November 21st 2024A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Read More
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
